In this article, we will take a look at the 5 Best Genomics Stocks to Buy According to Analysts. For a deeper discussion and an extended list, please see the 8 Best Genomics Stocks to Buy According to Analysts.
5. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Analysts’ Upside Potential: 43.75%
On May 28, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said partner GSK reported pivotal Phase 3 data for bepirovirsen. The corporation disclosed a 19% functional cure rate as compared to 0% on standard care, while reaching 26% in patients with lower viral activity. The trials, B-Well 1 and B-Well 2, met primary endpoints. Ionis stated that 233 of 1,220 treated patients achieved a functional cure versus none in the placebo group.
The company also reported 49% of treated patients reached surface antigen levels ≤100 IU/mL one year post-treatment, while 23% achieved sustained viral suppression at week 72.
Ionis mentioned adverse events included injection site reactions and temporary liver enzyme hikes.
Chief Executive Officer Brett P. Monia called the data “an important advance,” stating bepirovirsen could address chronic hepatitis B by reducing viral replication and suppressing surface antigen as well as stimulating an immune response.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is a firm that is involved in the development and marketing of human therapeutic drugs using antisense technology.
4. Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Analysts’ Upside Potential: 63.79%
On May 26, Pacific Biosciences of California, Inc. (NASDAQ:PACB) began global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform. The firm lowered the per-genome list price to $345 and authorized sub-$300 sequencing at scale. The company said the new chemistry cuts costs by about 30%. It also improved accuracy and yield through updates to its artificial intelligence-powered DeepConsensus algorithm developed with Google.
The company said beta testing across more than 1,400 runs showed higher yield and lower failure rates. Associate Professor and Senior Bioinformatician at Uppsala University, Adam Ameur, stated the system delivered “consistently strong run performance” with lower pricing and simplified workflows. CEO Christian Henry said AI advances, “improving data quality, speed, and usability,” are expanding what researchers can extract from each run.
Product Lead for Genomics at Google Research, Andrew Carroll, added that DeepConsensus upgrades introduce more data quality, while PacBio said expanded methylation detection and reusable consumables increase output and reduce costs.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a firm that develops, manufactures, and markets advanced sequencing solutions for genetic analysis. It operates through America, Europe, the Middle East, and Africa, and Asia Pacific segments.
3. Cerus Corporation (NASDAQ:CERS)
Analysts’ Upside Potential: 66.05%
On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providing up to $110 million. The firm combined a five-year term loan with an asset-backed revolving loan. The company said the refinancing will cut annual cash interest expense by up to $3.5 million while reducing its outstanding term loan balance by about $30 million.
The company used initial proceeds and cash on hand to retire its existing $65 million term loan. It also pulled an initial $35 million tranche at closing and secured access to an extra $30 million in staged increments. A separate five-year revolving facility of up to $45 million adds capacity and flexibility.
Chief Financial Officer Kevin Green said the refinancing “strengthens our financial foundation,” and pointed out extended maturities and lower borrowing costs. The corporation highlighted deferred amortization for 48 months, followed by a 12-month repayment period.
Cerus Corporation (NASDAQ:CERS) is involved in the research, development, and manufacturing of biomedical and surgical products.
2. Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts’ Upside Potential: 75.45%
On May 18, 2026, Beam Therapeutics Inc. (NASDAQ:BEAM) presented updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency at the American Thoracic Society International Conference. The firm detailed safety, durability, and reduced neutrophil elastase activity following treatment. It stated the data were made on topline results from 29 patients treated as of a February 10 cutoff, with extra insights from single-dose cohorts.
Chief Medical Officer Amy Simon said the findings support treating AATD “at the root cause of disease” using a one-time gene-editing therapy. Amy noted that Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing toward pivotal development. Separately, trial investigator John Hurst said the results suggest a single dose can restore AAT function, calling the approach “a paradigm shift.”
The company said it plans to pursue quick approval following FDA feedback, expecting to enroll about 50 more patients and start a pivotal cohort in the second half of 2026.
Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm. It is involved in the establishment of an integrated platform for precision genetic medicines.
1. Nurix Therapeutics, Inc. (NASDAQ:NRIX)
Analysts’ Upside Potential: 107.85%
On June 9, Truist analyst Gregory Renza raised Nurix Therapeutics, Inc. (NASDAQ:NRIX)’ price target to $32 from $30. The firm maintained a “Buy” rating on the shares. The analyst called the company’s partnership with Roche “strategically sensible.” It also cited a 50:50 US profit-share structure for bexdeg as justifiable, given potential execution gains in chronic lymphocytic leukemia and development into I&I and neurology. Truist added that the deal validates bexdeg’s broader clinical potential while strengthening Nurix’s balance sheet.
On June 8, Reuters reported that Roche entered an exclusive licensing and partnership agreement with Nurix Therapeutics, Inc. (NASDAQ:NRIX) worth up to $2.3 billion. The firm will receive $700 million upfront and milestone payments with development, regulatory, and sales targets. Roche said the deal centers on blood cancer drug bexobrutideg, with Phase III trials planned for the summer and potential launch around 2030. Deputy Chief Medical Officer Stefan Frings outlined the timeline, and Levi Garraway said the drug “could represent a major leap forward.”
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical business. It finds, develops, and commercializes innovative small molecules and antibody therapies based on cellular protein modification as a unique treatment method for cancer, inflammatory disorders, and other challenging diseases.
While we acknowledge the potential of NRIX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NRIX and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Most Profitable Small Cap Stocks to Buy and 8 Best Quantum Computing Stocks to Invest In According to Hedge Funds.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
